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Background: Despite entering complete remission after primary treatment, a substantial proportion of patients
with early stage breast cancer will develop metastases. Prediction of such an outcome remains challenging despite
the clinical use of several prognostic parameters. Several reports indicate that genomic instability, as reflected in
specific chromosomal aneuploidies and variations in DNA content, influences clinical outcome but no precise
definition of this parameter has yet been clearly established.
Methods: To explore the prognostic value of genomic alterations present in primary tumors, we performed a
comparative genomic hybridization study on BAC arrays with a panel of breast carcinomas from 45 patients with
metastatic relapse and 95 others, matched for age and axillary node involvement, without any recurrence after at
least 11 years of follow-up. Array-CGH data was used to establish a two-parameter index representative of the
global level of aneusomy by chromosomal arm, and of the number of breakpoints throughout the genome.
Results: Application of appropriate thresholds allowed us to distinguish three classes of tumors highly associated
with metastatic relapse. This index used with the same thresholds on a published set of tumors confirms its
prognostic significance with a hazard ratio of 3.24 [95CI: 1.76-5.96] p = 6.7x10-5 for the bad prognostic group with
respect to the intermediate group. The high prognostic value of this genomic index is related to its ability to
individualize a specific group of breast cancers, mainly luminal type and axillary node negative, showing very high
genetic instability and poor outcome. Indirect transcriptomic validation was obtained on independent data sets.
Conclusion: Accurate evaluation of genetic instability in breast cancers by a genomic instability index (G2I) helps
individualizing specific tumors with previously unexpected very poor prognosis.
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Table 1 Description of pair-wise groups
All n = 135 (%) pN0 n = 75 pN + n = 60
M- M+ M- M+ M- M+
Age < =55 n= 70 47 (35) 23 (17) 26 (35) 13 (17) 21 (35) 10 (17)
Age > 55 n = 65 43 (32) 22 (16) 24 (32) 12 (16) 19 (32) 10 (17)
All n = 135 90 (67) 45 (33) 50 (67) 25 (33) 40 (67) 20 (34)
n: Number of tumors; Age in years; pN0/pN+: absence/presence of lymph
node invasion; M- / M+: absence of detection/detection of distant metastasis
at 11 years.
Bonnet et al. BMC Medical Genomics 2012, 5:54 Page 2 of 18
http://www.biomedcentral.com/1755-8794/5/54Background
Despite entering complete remission after primary treat-
ment, a substantial proportion of patients with early
stage breast cancers will evolve towards metastatic re-
lapse, sometimes after a delay of many years [1]. Such an
evolution led to the concept of cell dormancy in which
the metastatic process results from the migration of indi-
vidual cells capable of forming a new tumoral localiza-
tion, even after a long latency [2]. This model, suggesting
heterogeneity of the metastatic power within the consti-
tutive cells of a primary tumor, found a new interest with
the hypothesis of the existence of cancer stem cells cap-
able to generate such secondary localizations [3].
Eliminating these cells is the objective of adjuvant
therapy which is given after optimal local treatment. Ef-
ficiency of such a therapeutic strategy is well established
[4], but accurate identification of patients for adjuvant
treatment requires appropriate prognostic factors that
are not clearly established. The main conventional prog-
nostic factor in early breast carcinoma is the staging of
axillary node involvement reflecting the cancer cells’
ability to diffuse and the level of invasion [5]. This criter-
ion however is not completely accurate in predicting pa-
tient outcome since 25% of patients without axillary
lymph node invasion show metastatic relapse at ten
years [6]. Among the many other factors that have been
tested, several show proven prognostic value such as
tumor size, histological grade [7], peritumoral vascular
emboli, or the expression of steroid hormone receptors
[8]. With the advent of gene expression profiling and the
identification of five intrinsic breast cancer subtypes
[9-11], prognosis in breast cancer is now considered
within each molecular subtype. Subsequent gene expres-
sion studies have identified prognostic transcriptomic
profiles that appear to be pertinent for the prognostica-
tion of short term relapses, specifically in estrogen re-
ceptor positive breast cancer [12,13].
The ability of gene signatures from bulk tumors to
predict metastatic relapse is difficult to reconcile with
the model putting forward that rare tumor stem cells
mediate metastasis [14]. It is necessary to conceive that
the various described prognostic signatures are the re-
flection of an intrinsic characteristic of cancer cells ra-
ther than a specific biological characteristic including
the ability to migrate and to form cell colonies outside
of the primary site [15]. Effectively, most of the proposed
prognostic signatures reflect an increased expression of
proliferation genes, one of the hallmarks of cancer [16].
Because another hallmark of cancer is loss of genetic
stability and because gene expression signatures linked
to chromosomal instability have shown some predictive
value for metastatic relapse in various kinds of cancer
[17, 18], we explore by array-CGH analysis the prognos-
tic value of genomic alterations in a series of breastcarcinomas with known outcomes after 11 years of
follow-up and confirm the main results obtained on
publicly available sets of tumors.
Methods
Patient samples
Tumor samples are from the tumor bank of “Institut
Bergonié” and come from 135 patients diagnosed with
invasive ductal carcinoma with surgical resection as first
treatment performed between 1989 and 1992. The study
was performed in accordance with Institut Bergonié’s
clinical research committee rules. All patients consented
to the use of their samples for research purposes, in
compliance with the French law on tumor banks (law n°
2004–800).
Forty-five tumor samples with metastatic relapse and
ninety samples without metastatic relapse were selected,
with a minimum follow-up of 131 months (11 years).
From each group, tumors were matched for patient age
at diagnosis (< or > to 55 years) and for axillary lymph
node involvement (Table 1). Mean patient age across
both groups was 55 years (range: 29 years-77 years).
Clinicopathological characteristics of tumors are given
in Additional file 1. Patients with tumors without axil-
lary lymph node involvement only received local treat-
ment (lumpectomy and radiotherapy, or mastectomy
with or without radiotherapy), whereas patients with
tumors with lymph node involvement received adjuvant
therapy, either chemotherapy or hormone therapy, ac-
cording to the procedures used at the time.
Array CGH
– Sample preparation
A fragment of tumoral tissue was immediately snap
frozen in liquid nitrogen after surgical removal and
stored at −140°C in the tumor bank of “Institut
Bergonié”. After grinding in liquid nitrogen, DNA
was purified according to a standard methodology
based on organic solvents.
– Micro-array hybridization
Array-CGH was performed on human Integrachip
V7 slides (Integragen SA, Evry, France, http://www.
integragen.com). IntegraChip V7 is composed of
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clones. BAC clones are spotted in quadruplicate.
Hybridizations were performed according to the
manufacturer’s recommendations (see Additional
file 2).
– Data analysis
The CAPweb (Copy number Array analysis Platform
on the web) developed by Institut Curie (CAPWeb,
http://bioinfo-out.curie.fr/CAPweb/) was used for
normalization (MANOR package), segmentation and
smoothing (GLAD package) as detailed in
Additional file 2. Graphical representation of
genomic alterations was performed with VAMP
software (http://bioinfo.curie.fr/vamp)[19]. Gains
and losses were defined as values of Cy3 to Cy5
smoothed log2 ratio more than the standard
deviation between normalized and smoothed log
2 ratio for all the autosomes (see Additional file 2
for details). The array-CGH data are available in the
ArrayExpress database (http://www.ebi.ac.uk/
arrayexpress/ accession number: E-MTAB-748).Expression profiling
Rneasy Mini Kits (Qiagen, Courtaboeuf, France) were
used to extract total RNA from samples, ground to
powder while frozen. RNA quality was assessed using
the Agilent 2100 Bioanalyzer (Agilent Technologies).
Gene-expression analyses were performed by the IGBMC
and Génopole Alsace-Lorraine Affymetrix service using
Affymetrix U133 Plus 2.0 genechip microarrays as de-
tailed in Additional file 2. The transcriptomic data are
available in ArrayExpress database (http://www.ebi.ac.uk/
arrayexpress/ accession number: E-MTAB-748).Tissue micro-array and immunohistochemistry
Corresponding Holland Bouin-fixed paraffin-embedded
tumor blocks were retrieved from the hospital files and
were used to construct a tissue microarray (TMA) com-
prising four representative 0.6 mm cores for every tumor.
The TMA was made with an Alphelys tissue arrayer.
Immunohistochemical analysis was performed on a Dako
autostainer as described in Additional file 2. An im-
munohistochemical transposition of the transcriptomic
intrinsinc molecular classification of breast cancer was
performed according to Nielsen et al. [20]. Luminal type
A tumors were ER or PR positive (≥ 10% positive tumor
cells) with a Mib1 proliferation index <20% and Her2
scores 0, 1+ or 2+. Luminal type B tumors were ER or PR
positive with a Mib1 proliferation index ≥ 20% or a Her2
score 3+. Her2-enriched tumors were ER and PR nega-
tive and Her2 score 3+. Finally Basal-like tumors were
ER and PR negative, Her2 0, 1+ or 2+ and CK5/6 or
EGFR positive.TP53 mutation analysis
TP53 coding exons (2–11) were amplified as 7 ampli-
cons (exons 2 and 3, 5 and 6, 8 and 9 respectively in a
same amplicon) which were screened for point muta-
tions through a combination of dHPLC followed by se-
quencing of variants (exons 4–11) or sequencing directly
(exons 2–3) on a 3130XL ABI DNA sequencing ma-
chine. Primer sequences and PCR conditions are avail-
able on request.
Statistical considerations
Clustering of genome copy number profile
Samples were clustered based on “gain, normal, loss”
(GNL) data, using an Agglomerative Hierarchical Clus-
tering (described in Additional file 2). The number of
groups (n = 6) was assessed qualitatively by considering
the shape of the clustering dendrogram and the homo-
geneity of the chromosomal rearrangements within each
cluster.
Genomic instability index (G2I)
The proposed score is based on two items: (i) the overall
level of genomic alteration (noted A) and (ii) the number
of altered genomic regions (noted N). By applying a set
of appropriate thresholds on these two items, we can de-
fine three groups with genomic scores 1, 2 and 3, char-
acterized by an increasing level of genomic perturbation.
For a given sample i, let Ni and Ai be respectively the
computed values N and A. Let a1, a2, n1, and n2 be the
thresholds:
If Ai < a1 and Ni < n1 then genomic score = 1 (low level
of perturbation)
If Ai > a2 and Ni > n2 then genomic score = 3 (high level
of perturbation)
Else genomic score = 2 (average level of perturbation)
The calculation of A and N as well as the estimation
of the thresholds a1, a2, n1, and n1 are described in
Additional file 2. The R script that allows reproducing
the results is provided in supplemental data (Additional
file 3).
Predictive analysis
A univariate logistic regression model was used to define
the odd ratios between the G2I classes and metastatic
relapse as well as for the classical prognostic parameters.
Factors significant at p < 0.05 in univariate analysis were
included in a maximum likelihood logistic regression
model in ascending order.
Validation
An external validation using publicly available BAC
arrays CGH data from 168 invasive ductal carcinomas of
the breast [21] was performed. This set of tumors, in-
cluding 57 cases with metastatic relapse and 111 tumors
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a follow-up of at least 5 years (median follow-up:
130 months; range: 71–210), consists only of node nega-
tive breast cancers. Array-CGH data are from 6 distinct
BAC arrays but similar to this one used in the pre-
sent study. Application of the G2I to this set of tumors
using the previously defined thresholds is described in
Additional file 2.
Transcriptomic signature of the G2I-3 tumors
To identify genes differentially expressed between G2I-
1/2 and G2I-3 tumors, based on the RMA log2 single-
intensity expression data, we used Welch’s T-tests (t-test
function, R package stats) with a threshold of 5x10-3 on
p values leading to 300 probe sets (associated to 222
unique EntrezGene symbols). Then, samples were clus-
tered based on this signature using an Agglomerative
hierarchical clustering.
Comparison of four prognostic molecular signatures in
three independent datasets
The molecular signature deduced from the genomic in-
stability index (G2I) was compared to three well-known
prognostic signatures: Amsterdam [22], GGI of Sotiriou
[23] and the intrinsic gene sets used by Sorlie et al. to
identify their five molecular subtypes [11]. The four sig-
natures were applied to independent datasets according
to an approach inspired from Fan et al. [24] and
described in Additional file 2. This comparison is done
in three independent datasets corresponding to i) this
study, ii) the Rotterdam study [25] and iii) the Loi study
[26].
Results
Unsupervised clustering of array-CGH data identifies six
groups of tumors
To identify broad patterns of large scale genomic re-
arrangement, we performed unsupervised clustering
based on the “gain, normal, loss” (GNL) profile of each
tumor (Figure 1). The clustering of the tumors into six
main groups was driven mainly by gains or losses of
whole chromosomal arms, particularly on chromosomes
1, 7, 8, 11, 16, 17 and 20. The dominant changes in each
group are more readily seen in whole genome plots show-
ing the cumulative changes at each locus (Figure 2A).
The groups are labeled according to the clusters in
Figure 1, which are described below.
“Cluster a” comprises tumors without recurrent
changes affecting any particular chromosome. The only
copy number change seen in more than 60% of cases
was loss of 17p13 (Additional file 1 and Figure 2A-a).
Copy number variations involving small genomic regions
can be observed, sometimes frequently in a same tumor,but without recurrence of a specific change from one
tumor to another.
“Cluster b” comprises tumors with gains of the long
arm of chromosome 1 and losses of the long arm of
chromosome 16, a common rearrangement frequently
linked to the well-known unbalanced translocation t
(1;16). The only other rearrangements were losses of 8p
and 11q observed in nearly 50% of the tumors
(Additional file 1 and Figure 2A-b).
“Cluster c” comprises tumors with two chromosomal
rearrangements, gain of 1q and gain of the entire
chromosome 7 which were present in 80% of the tumors
in this cluster. To our knowledge, the specific associ-
ation of both of these chromosome rearrangements was
not previously noted in breast cancer. Other common
changes were loss of 12p13 and gain of 8q (Additional
file 1 and Figure 2A-c).
“Cluster d” comprises tumors characterized by the as-
sociation of rearrangements of chromosomes 8 and 16
with loss of the entire 8p and 16q arms and gain of the
8q and 16p arms in nearly 100% of cases. Other chro-
mosomal rearrangements are less frequently associated,
such as loss of 6q, loss of 13q and loss of 17p. Interest-
ingly, some specific rearrangements affecting small
regions are observed with high frequency in this specific
group of tumors. These are gains of 5p14, 12q13, 15q22,
17q11.2, and loss of 12p13 like in cluster c tumors
(Additional file 1 and Figure 2A-d). Genes located within
these tiny rearranged genomic regions are listed in
Additional file 1.
“Cluster e” comprises tumors with a more complex
pattern involving numerous chromosomal arms and
regions within arms. The main rearrangements were loss
of 1p with a more frequently deleted region at 1pter,
gains of 1q and of 8q, and losses of 11q and of 16q.
Some regions of gain or loss observed in 50% of the
tumors show a more reduced segment with higher fre-
quency of rearrangement. Specifically, these were: gain
of the entire chromosome 5 with a specific gain at 5p14;
loss of 6q with a specific loss at 6q16; gain of 12q with
specific gain at 12q21; gain of 16p with specific gain at
16p13; gain of 17q with specific gain at 17q11; gain of
20q with a specific gain at 20q13.2. Moreover, two tiny
regions show specific rearrangement. They are: gain of
4q35 and loss of 12p13 as in the two previous clusters
(Additional file 1 and Figure 2A-e). Genes located at
these specific loci are listed in Additional file 1.
“Cluster f” comprises tumors with a highly rearranged
pattern. The largest recurrent changes were gain of 16p
and 20q but most changes involved much smaller gen-
omic regions scattered throughout the genomes. The
large number of rearrangements did not allow any de-
scription but similar genomic regions seem involved
since it is possible to identify at least 74 loci for which a
Figure 1 tumoral classification according to array CGH genomic profile. Unsupervised hierarchical clustering using genomic copy number
variation enables the classification of the 135 breast carcinomas into six branches. MR, black: metastatic relapse; HR, black: positive for steroid
hormonal receptors; Her2, black: Her2 score 3+; p53, black: TP53 mutation or protein overexpression; NPI (Nottingham prognostic index) red:
NPI-1, blue: NPI-2, green: NPI-3, orange: NPI-4; G2I (genomic instability index) red: G2I-1, blue: G2I-2, green: G2I-3.
Bonnet et al. BMC Medical Genomics 2012, 5:54 Page 5 of 18
http://www.biomedcentral.com/1755-8794/5/54genomic loss is observed in more than 80% of the
tumors in this cluster (Figure 2A-f ). This pattern of ex-
treme rearrangement constituted the specter of a spe-
cific DNA breakage syndrome or DNA repair defect.
The outcome of patients belonging to these groups of
tumors does not show any major difference for the five
first clusters even though clusters a, b, and d show a lit-
tle better prognosis than cluster c and e (Figure 2B).
Conversely, patients belonging to cluster f had a very
poor outcome since ten tumors out of twelve belonging
to this group showed metastatic relapse during the time
of the survey (Figure 2B).
Amplicons were most common in cluster f
By defining amplicons as regions whose copy number is
over three for at least two contiguous clones, 64 tumorscontained at least one amplicon. A total of 90 distinct
regions were amplified involving all chromosomes ex-
cept chromosomes 2, 9, and 13. The number of ampli-
cons per tumor ranged from one amplicon (13 tumors)
to seventeen (one tumor). The mean was five amplicons
for these 64 tumors. The size of amplicons ranged from
a few kilobases containing one or a few genes as 6q25
amplification and ADR1 or 14q24.3 amplification and
FOS (Additional file 1), to tens of megabases. As ex-
pected, the classic known breast cancer amplicons were
the most common, including the CCND1 amplicon at
11q13 in 18 tumors, the ERBB2 amplicon at 17q12 in
17 tumors followed by 8p12 and 20q amplicons in 11
tumors.
Amplicons were seen in all the CGH clusters but their



























































Figure 2 genomic characteristics and prognostic value of each array CGH cluster. (A): Frequency plot of copy number variation showing
the dominant genomic changes in each array CGH cluster. (B): Kaplan Meier curves showing the poor outcome of cluster “f” tumors according to
the other array CGH groups.
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tumor was more specific. On average, there were only two
amplicons per tumor in clusters a-e, but five in cluster f
(Table 2). The increase in low level copy number changes
in cluster f was thus accompanied by a corresponding
increase in amplicons.
An array CGH-based index of genomic instability is
predictive of clinical outcome
Due to evidence of a correlation between a highly rear-
ranged genome (at the level of copy number variation,breakpoints, gene amplification) and clinical outcome,
we built an index of genetic instability based on two
parameters linked to the array CGH GNL status.
The first one corresponds to the fraction of the gen-
ome altered. It is the mean by chromosome arm of the
proportion of lost or gained clones. This parameter var-
ies from 0.004 to 0.73, with a mean value of 0.28.
The second one, corresponding to the number of
altered genomic regions reflects the number of break-
points within the genome. It is the total number of gen-
omic regions showing a difference in copy number
Table 2 Amplicons and p53 alterations according to array CGH clusters and G2I classes of tumors (%)
All Array CGH clusters G2I classes
a b c d e f 1 2 3
Total tumors 135 34 25 16 13 35 12 19 88 28
Tumors with amplicons 64 (47) 14 (41) 8 (32) 10 (63) 7 (54) 17 (49) 8 (67) 3 (16) 41 (47) 20 (71)
Amplicons 296 60 43 37 24 69 63 6 173 117
Amplicons per tumor (mean) 2.2 1.8 1.7 2.3 1.8 2.0 5.3 0.3 2.0 4.2
Amplicons per tumor in tumors with amplicons (mean) 4.6 4.3 5.4 3.7 3.4 4.1 7.9 2 4.2 5.9
5q23.3 (a) 7 (5) 2 ( 6) 3 (12) 0 0 2 ( 6) 0 0 5 (6) 2 (7)
8p12a or 8p12-p11 11 (8) 2 (6) 1 (4) 2 (8) 3 (23) 2 ( 6) 1 (8) 0 8 (9) 3 (11)
11q13.2-q13.3 18 (13) 4 (12) 1 (4) 2 (8) 0 8 (23) 3 (25) 1 (5) 9 (10) 8 (29)
11q14.1a 11 (8) 3 (9) 0 2 (13) 0 5 (14) 1 (8) 1 (5) 7 (8) 3 (11)
12q13.11-q13.12 7 (5) 1 (3) 1 (4) 0 0 3 (9) 2 (17) 0 4 (5) 3 (11)
17q11.2b 6 (4) 1 (3) 1 (4) 0 0 2 (6) 2 (17) 0 3 (3) 3 (11)
17q12e 17 (3) 4 (12) 3 (12) 1 (4) 4 (31) 4 (11) 1 (8) 1 (5) 12 (14) 4 (14)
17q21.1-q21.2 8 (6) 2 (6) 2 (8) 0 2 (15) 2 (6) 0 1 (5) 5 (6) 2 (7)
17q21.31 8 (6) 1 (3) 0 1 (6) 2 (15) 3 (9) 1 (8) 1 (5) 5 (6) 2 (7)
17q21.33 8 (6) 1 (3) 0 1 (6) 2 (15) 2 (6) 2 (7) 0 4 (5) 4 (14)
20q (b) 11 (8) 3 (9) 1 (4) 0 0 3 (9) 4 (33) 0 5 (6) 6 (21)
p53 alteration (c) 39 (29) 11 (32) 5 (17) 5 (31) 4 (31) 7 (20) 7 (58) 0 24 (27) 15 (54)
a) number of tumors (%) with the 11 most recurrent amplicons described in Additional file 2 b) tumors with at least one amplicon on 20q: at 20q11.21 , 20q13.2 or
20q13.31-q32; c) TP53 mutation or immunohistochemistry p53 accumulation.
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to reduce the number of artifacts, we use a “local score”
calculation to attribute a similar status (i.e. gain, normal
or loss) to a genomic segment (see Additional file 2).
The number of altered regions varies from 19 to 129
(mean: 64.7).
As shown in Figure 3A, the 135 tumors spread in a
cloud of points with a very faint correlation between the
two parameters. Tumors with chromosomal aneusomies
are predominantly plotted in the lower right quadrant
while tumors with numerous small rearrangements lie in
the upper left quadrant (Figure 3B). In applying relapse
status to each tumor (dark points on Figure 3A), it
appears that the two tumoral populations (i.e. with and
without relapse) show a large median overlap but that
tumors lying in the lower left quadrant have a lower risk
of relapse than tumors in the upper right quadrant thus
individualizing three populations of tumors.
To define three grades of genomic instability, we
adjusted thresholds for the two parameters that best
discriminate tumors according to outcome (see the
Additional file 2 for details).
Tumors in the low risk region (G2I-1 for Genomic
Instability Index - grade 1) showing an overall level of
genomic alteration below 48% and a number of altered
regions < = 42, relapsed in one case out of 19. Tumors
in the high risk region (G2I-3, for Genomic Instability
Index - grade 3) showing an overall level of genomicalteration above 35% and a number of altered regions
> = 65 relapsed in 21 out of 28 cases. The difference
in risk of relapse between the G2I-1 and G2I-2 tu-
mors was borderline significant (Odd ratio: 0.16 [0.2-1.2]
p = 0.08) whereas that between the G2I-2 and G2I-3
tumors was highly significant (odd ratio: 8.5 [3.2-22.6]
p < 0.001) in univariate analysis. Similar results were
obtained in multivariate analysis adjusted on the
Nottingham Prognostic Index (NPI) (Table 3). The
contribution of each CGH cluster class to the three G2I
groups is shown in Table 4 and examples of array CGH
profiles from the four quadrants of the scatter plot are
provided in Figure 3B.
Validation of the G2I on an independent data set
To validate the G2I on independent data, we analyzed
168 breast cancers without axillary lymph node involve-
ment for which BAC array CGH data were available
[21]. In this dataset, 57 patients developed metastases
while 111 others did not show metastatic or loco re-
gional recurrence after at least 5 years of follow-up (me-
dian follow-up: 10.8 years). Using the previously defined
thresholds, the G2I could predict clinical outcome with
a p-value of 1.08x10-5 (logrank test) since, among tu-
mors scored as G2I-3, 74% developed metastases,
whereas in the G2I-1 group only 16% did (Figure 4A).
The ten year metastasis–free survival (Figure 4B) ana-
lyzed with the log-rank test showed a highly significant



































































Figure 3 (See legend on next page.)
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Figure 3 Distribution of the tumors according to the genomic instability index (G2I). (A) Scatter plot of the 135 tumors according to the
two items of the G2I. Thresholds are marked by dash lines: overall level of genomic alteration < 0.48 for G2I-1 and > 0.35 for G2I-3, number of
altered regions < 42 for G2I-1 and > 65 for G2I-3. M+: metastatic relapse, M- absence of relapse after 11 years of follow-up. Circles: tumors for
which genomic profile is showed in B. (B) Examples of array CGH profiles of G2I tumors according to their position on the scatter plot. Lower left
quadrant: flat profile with few rearrangements; lower right quadrant: profile with predominantly whole arm changes; upper left quadrant: profile
with predominantly breakpoints; upper right quadrant: highly rearranged profile with huge number of breakpoints.
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(hazard ratio: 3.24 [95CI: 1.76-5.96] p = 6.7x10-5 and (ii)
a borderline significant difference between the G2I-1
and G2I-2 groups (hazard ratio: 2.29 [95CI: 0.90-5.78]
p = 0.072).Table 3 Association with relapse in the study group for the G
Clinicopathological parameters All (a) n(%) No Relapse n(%)
G2I (b)
Class 1 19 (14) 18 (20)
Class2 88 (65) 65 (72,2)
Class3 28 (21) 7 (7,8)
SBR Grade (c)
1 25 (18) 21 (23,3)
2 71 (53) 46 (51,1)
3 39 (29) 23 (25,6)
Histological size
≤ 20 mm. 90 (67) 67 (74,4)
> 20 mm. 45 (33) 23 (25,6)
HR status (d)
HR- 19 (14) 12 (13,3)
HR+ 116 (86) 78 (86,7)
NPI (e)
1 + 2 30 (22) 24 (26,7)
3 85 (63) 58 (64,4)
4 20 (15) 8 (8,9)
TP53 alteration
no 115 (85) 73 (81,1)
yes 20 (15) 17 (18,9)
mib1 (f)
<20% 93 (69) 67 (74,4)
≥20% 42 (31) 23 (25,6)
IHC intrinsic class (g)
LA 83 (62) 59 (67)
LB + Her2+ Basal 50 (38) 29 (33)
nd 2 2
(a) n: Number of tumors; % in parentheses; (b) G2I: Three classes of genomics instab
Hormonal Receptor; HR-: negative hormonal receptor status evaluated by immunoh
Prognostic Index, 1 + 2: good or excellent, 3: moderate, 4: poor; (f) immunohistochem
A for HR+-tumors with mib1 expression in less than 20% of tumor cells, LB: Lumina
Her2 score of 3, Her2: Her2-enriched tumors for HR- and Her2+-tumors, Basal for HR
than 10% of tumor cells: egfr, ck5/6, or vimentin;Comparison of the G2I and the array CGH clusters
with classical prognostic parameters
The tumors used in this study were matched for age and
axillary lymph node involvement but not for other fac-
tors, such as the size of the tumors, the histological2I and for various clinicopathological parameters
Univariate analysis Multivariate analysis
Relapse n(%) OR [CI 95%] p OR [CI 95%] p
1 (2,2) 0,16[0,2-1,2] 0,08 0,24[0.03-2] 0.19
23 (51,1) 1 1
21 (46,7) 8,5[3 ,2-22,6] <0,001 11.9[4.2-34.1] <0.001
rejected
4 (8,9) 1
25 (55,6) 2,9[0,9-9,2] 0,08
16 (35,6) 3,7[1,05-12,7] 0,04
rejected
23 (51,1) 1
22 (48,9) 2,8[1, 3–5, 9] 0,008
7 (15,6) 1,19[0 ,44- 0,72
38 (84,4) 3,3]
6 (13,3) 1 1
27 (60) 1,8[0,7-5,1] 0,23 1.38[0.4-4.4] 0.6
12 (26,7) 6[1,7-21,3] 0,006 7.2[1.8-29.3 0.006
31 (68,9) 1
14 (31,1) 1,9[0,9-4,4] 0,11
rejected
26 (57,8) 1
19 (42,2) 2,1[1–4,5] 0,05
24 (53,3) 1
21 (37,6) 1,8[0,85-3,7] 0,12
ility index as defined here; (c) SBR: Scarff, Bloom and Richardson grade; (d) HR:
istochemistry (IHC) with a threshold of 10% of tumors cells; (e) NPI: Nottingham
istry expression of mib1; (g) immunohistochemical intrinsic class: LA: Luminal
l B for HR+-tumors with mib1 expression in at least 20% of tumor cells or with
- and Her2--tumors that express at least one of the following protein in more
Table 4 distribution of the three classes of G2I according to array-CGH clusters (%)
Cluster a n = 34 Cluster b n = 25 Cluster c n = 16 Cluster d n = 13 Cluster e n = 35 Cluster f n = 12 All n = 135
G2I-1 6 (18) 6 (24) 3 (19) 1 ( 8) 3 ( 9) 0 19 (14)
G2I-2 26 (76) 19 (76) 10 (62) 12 (92) 21 (60) 0 88 (65)
G2I-3 2 ( 6) 0 3 (19) 0 11 (31) 12 (100) 28 (21)
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http://www.biomedcentral.com/1755-8794/5/54Scarff Bloom and Richardson (SBR) grade or the hormo-
nal receptor (HR) status.
A search for correlations between the G2I and classical
prognostic factors did not show any correlation for
histological size, steroid hormone receptor status, or
Nottingham prognostic index (NPI) (Table 5). There was
a correlation with the intrinsic classification although
the basal tumors belong mainly to the G2I-2 group
(Table 6) and with the Mib1 status suggesting a link with
proliferation (Table 5).
Interestingly, the G2I-3 remains associated with re-
lapse with respect to the G2I-2 group in the following
subgroups: tumors smaller than 20 mm (OR: 5.6 [1.7-17]
p = 0.004); SBR grade 2 and 3 tumors (OR: 9.9 [1.9-51.5]
p = 0.006 and OR: 10.6 [2.2-51.4] p = 0.004 respectively);
steroid hormone receptor-positive tumors (OR: 8.37
[2.9-24.2] p < 0.001); NPI class 3 (moderate) tumors
(OR: 14.5 [3.5-60.8] p < 0.001) and axillary lymph node
negative tumors (OR: 17.5 [4.6-66.7] p < 0.001). This last
result reflects the higher proportion of node negative
tumors in the G2I-3 group than in the G2I-2 group
(71% and 49% respectively; Additional file 4). Overall,
tumors with grade 3 genetic instability were mainly lu-
minal and lacked axillary lymph node involvement, but
had a very high risk of metastatic relapse.
Correlation with TP53 mutations
Because of the link between p53 and genome stability,
we searched for alterations of the TP53 gene directly by
DNA sequencing and indirectly by immunohistochemis-
try (IHC) for increased p53 protein expression. Point
mutations were detected in 31 tumors (20 missense
mutations and 11 truncated mutations) and p53 IHC ex-
pression was detected in 28 tumors with a good correl-
ation between missense mutation and protein expression
(Table 7).
The presence of a TP53 alteration (either a mutation
or an increase in protein detection) was correlated with
the G2I (Table 5) (p =0.0003). No TP53 alterations were
detected in the G2I-1 tumors compared with TP53
alterations which were found in 54% of the G2I-3
tumors (Table 2). TP53 alterations were observed in all
CGH clusters with a frequency of 20-30% of tumors in
clusters a to d compared with 58% for tumors in the
highly unstable cluster f (Table 2). The expected pattern
of TP53 alterations was seen with respect to intrinsic
classification: mutations or increased protein expressionwere seen in 70%, 57%, 42% and 15% of HER2-enriched,
basal- like, luminal B and luminal A tumors, respectively.Genomic rearrangements specific to G2I-3 tumors
Tumors belonging to the G2I-3 group showed a high
level of genetic alteration with a large number of small
regions showing copy number variation, mainly losses.
Some alterations were recurrent and specific to this
group indicating a possible selection for these rearrange-
ments. Additional file 4 shows the frequencies of gain and
loss for each clone in the three G2I groups. Genomic
regions showing significantly more gains or losses in the
G2I-3 tumors compared with the two other groups of
tumors with a p value < = 10-4 and a frequency of ≥ 50%
are listed in Additional file 1. Six regions on chromosomes
12, 16, 17, and 20, show specific gains for the G2I-3
tumors, and a further 49 regions show specific genomic
losses. Most regions contained multiple genes but a few
were small enough to allow identifying potential driver
genes mentioned in Additional file 1.A gene expression signature specific to G2I-3 tumors
High quality RNA was available for 46 of the 135
tumors. Fifteen of these belong to the G2I-3 group, 29
to the G2I-2 group, and two tumors to the G2I-1 group.
We hybridized cDNA from these tumors to Affymetrix
U133 Plus 2.0 genechips. Supervised analysis allowed us
to define a signature of 300 probe sets showing differen-
tial expression between 14 of the 15 G2I-3 tumors and
the rest (Additional file 4). The list of genes for which
over or under expression is specific for G2I-3 tumors is
provided in Additional file 1. The genes in this signature
are not specifically linked to cell proliferation or to any
DNA repair system. Several of the genes over-expressed
in G2I-1 + 2 tumors are involved in signal transduction,
in particular the hedgehog, VEGF and MAPK pathways
(Additional file 1). The genes best distinguishing G2I-2
from G2I-3 tumors are not specifically localized at re-
arranged genomic regions (Additional file 1). However,
several over-expressed genes belonging to this signature
are located at genomic regions specifically gained in G2I-3
tumors such as JAG1 at 20p12.2 or RPN2, C20orf117, and
DHX35 at 20q11.23. Conversely, under-expressed genes
are located at specifically lost regions such as CD 109
at 6q13, ELOVL4 at 6q14.1, C9orf46, KIAA1432 and


































Overall level of genomic alteration
G2I-2/G2I-1 – HR: 2.29 [95CI: 0.90; 5.78] p=0.072
G2I-3/G2I-2 – HR: 3.24 [95CI: 1.76; 5.96] p=6.7x10-5
Figure 4 Prognostic value of the G2I on independent data set. (A) Scatter plot of 168 breast cancers from which BAC array CGH data were
available [21] according to the two items and the previously defined thresholds of the G2I. M+: metastatic relapse; M-: absence of local or
metastatic relapses after five years of follow-up. (B): Kaplan Meier curves showing metastasis-free survival at 10 years for the three G2I classes.
Green: G2I-1, blue: G2I-2, red: G2I3; the number of tumors in each G2I class is given in parenthesis. HR: hazard ratio (log-rank test).
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Table 5 Association between G2I classes and clinico-pathological parameters
Clinicopathological Parameters Total n = 135 (%) G2I-1 19 G2I-2 88 G2I-3 28 χ2 test p-value
Lymph node involvement
pN0 75 (56) 12 (63) 43 (49) 20 (83) 0.086
pN+ 60 (44) 7 (37) 45 (51) 8 (29)
Age (years)
<=55 70 (52) 8 (42) 51 (58) 11 (39) 0.149
>55 65 (48) 11 (58) 37 (42) 17 (61)
Histological size (mm)
<= 20 90 (67) 16 (84) 57 (65) 17 (61) 0.2
> 20 45 (33) 3 (16) 31 (35) 11 (39)
Scarff Bloom Richardson (SBR) Grade
1 25 (18) 6 (32) 15 (17) 4 (14) 0.037
2 71 (53) 12 (63) 48 (55) 11 (39)
3 39 (29) 1 ( 5) 25 (28) 13 (39)
Steroid Hormone Receptor status
HR+ : > = 10% 116 (86) 18 (95) 74 (84) 24 (86) 0.48
HR- 19 (14) 1 ( 5) 14 (16) 4 (14)
Nottingham prognostic index (NPI)
1 + 2 30 (22) 6 (32) 20 (23) 4 (14) 0.37
3 85 (63) 13 (68) 50 (57) 22 (79)
4 20 (15) 0 ( 0) 18 (20) 2 ( 7)
Mib1
<20% 93 (69) 18 (95) 60 (68) 15 (54) 0.011
≥20% 42 (31) 1 ( 5) 28 (32) 13 (46)
Ihc intrinsic classification(a)
LA 83 (62) 16 (84) 55 (64) 12 (43) 0.014
LB + her2+ Basal 50 (38) 3 (16) 31 (36) 16 (57)
unclassified 2 0 2 0
p53 status (b)
- 95 (71) 19 (100) 64 (73) 13 (46) 0.0003
+ 39 (29) 0 ( 0) 24 (27) 15 (54)
At least one amplicon
No 71 (53) 16 (84) 47 (53) 8 (29) 0.001
Yes 64 (47) 3 (16) 41 (47) 20 (71)
(a) immunohistochemistry based on intrinsic classification, LA: luminal A, LB: luminal B, Her2: Her2-enriched; (b) TP53 mutation or immunohistochemical detection
of p53 accumulation.
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constitution of a part of the signature.
To test whether this signature has independent prog-
nostic value, we compared it to three previously pub-
lished prognostic signatures in three independent data
sets including ours. The results are summarized in
Figure 5. The Amsterdam signature [22], the genomic
grade index (GGI) [23], and the intrinsic gene set [11]
were all able to split the tumors into two groups ac-
cording to outcome in the three sets of tumors. Asexpected, the G2I signature gave the best results for our
own data set (p = 5.4x10-6) compared to the results for
these tumors with the Amsterdam, GGI and intrinsic
signature (p = 0.8; p = 0.32; and p = 0.002 respectively).
The G2I transcriptomic signature also showed higher
prognostic value than the three other signatures in the
Rotterdam study [25]. It showed higher prognostic value
(p = 6.4x10-4) than the Amsterdam and intrinsic sig-
nature (p = 0.015 and p = 0.004 respectively) in the Loi
study [26] but the GGI signature gave the best results in
Table 6 Distribution of the tumors within the immunohistochemistry intrinsic classes according to SBR grade and array
CGH-based genomic characteristics
All n = 135 (%) Luminal A n = 83 Luminal B n = 33 HER2-enriched n = 10 Basal n = 7 Unclassified n = 2
SBR Grade
1 25 (18) 24 (29) 0 0 1 (14) 0
2 71 (53) 53 (64) 16 (49) 1 (10) 0 1
3 39 (29) 6 ( 7) 17 (52) 9 (90) 6 (86) 1
Array CGH clusters
a 34 (25) 17 (20) 5 (15) 5 (50) 6 (86) 1
b 25 (18) 20 (24) 3 ( 9) 2 (20) 0 0
c 16 (12) 7 ( 8) 8 (24) 0 0 1
d 13 (10) 9 (11) 3 ( 9) 1 (10) 0 0
e 35 (26) 23 (28) 11 (33) 1 (10) 0 0
f 12 ( 9) 7 ( 8) 3 ( 9) 1 (10) 1 (14) 0
Nb. of amplicons
0 71 (53) 56 (67) 7 (21) 1 (10) 6 (86) 1
≥1 64 (47) 27 (33) 26 (79) 9 (90) 1 (14) 1
Range 1–17 1–10 1–17 1–11 NA 1
Mean 4.9 3.6 5.6 4.9 9 1
G2I classes
1 19 (14) 16 (19) 2 ( 6) 1 (10) 0 0
2 88 (65) 55 (66) 19 (58) 6 (60) 6 (86) 2
3 28 (21) 12 (15) 12 (36) 3 (30) 1 (14) 0
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http://www.biomedcentral.com/1755-8794/5/54these tumors, on which it was trained (Figure 5). We
conclude that genomic instability is an important marker
of poor prognosis whether it is assessed directly with
CGH data or indirectly with gene expression data.
Discussion
Array CGH analysis of breast carcinoma both on BAC
array and on oligo array had previously highlighted the
genomic heterogeneity of these tumors. The most popu-
lar classification distinguishes three classes of tumors.
The first one, characterized by only few rearrangements
is called “simplex” [1,27] or “1q/16q” [28,29], the second,
called “complex sawtooth” [27,30] or “complex” [28,29],
is characterized by a large number of rearrangements,
including breakpoints and copy number variations for
very small genomic segments. The third one calledTable 7 p53 alterations




All (%) 103 (77) 31 (23)
(a) +: Immunohistochemical detection of p53 accumulation in at least 10% of tumor
Additional file 2), -: wild type TP53; (c) ms: missense mutation, tm: truncated mutatio“complex firestorm” [27,30] or “mixed amplifier”, [28,29]
is characterized by a phenomenon of gene amplification
with a high copy number variation restricted to small
genomic regions. Indeed, it is possible to allocate some
specific tumors to such a class of genomic profiles and
for example, tumor number 83 in our series showed a
simplex profile with only a 1q gain and 11q and 16 q
losses as sole rearrangements, tumor number 43 showed
a typical complex sawtooth profile, and tumor number
100 a mixed amplifier profile. However, a large number
of tumors in our series showed intermediary patterns
and it was not possible to assign them to a specific class.
For example, tumor number 7 showed a relatively flat
profile with several amplicons on chromosomes 6 and 17
and tumor number 47 showed an intermediary profile
between simplex and complex sawtooth.Type of TP53 mutation (c) All (%)
ms tm
1 10 107 (80)
19 1 27 (20)
20 (15) 11 (8) 134 (100)
cells, -: no p53 signal; (b) +: detection of a mutation of TP53 (listed in











































































   
   
   
   
   
   
   
   
   
   
   
   
   








































































































































































































































Figure 5 comparison of prognostic value of the G2I transcriptomic signature with three other prognostic signatures. Kaplan Meier
curves showing the prognostic value of the G2I transcriptomic signature (line 1), of the 70-gene Amsterdam signature (line 2), of the Gene
expression Grade Index (line 3) and of the intrinsic subtypes (line 4) on three independent sets of tumors. Column A: this study, column B:
the Rotterdam study [25], column C: the study by Loi et al. [26].
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http://www.biomedcentral.com/1755-8794/5/54In fact, three kinds of genomic rearrangements related
to various kinds of genetic instability are detectable by
array CGH methodologies. They are: i) whole chromo-
somal or whole chromosomal arm aneusomies related
respectively to mitotic malsegregation or centromeric re-
arrangement, ii) DNA breakpoints with repair defects
resulting in copy number variation for short genomic
segments and iii) gene amplification. These three kinds
of genomic rearrangements are more or less associated
in a single tumor and show a continuous variation with
a growing level of intensity from one tumor to another.Thus, a true classification based on genomic alteration
criteria remains difficult to implement. The results ob-
tained here suggest that it is possible to distinguish be-
tween two groups of tumors. One group shows gain or
loss of entire chromosomes or entire chromosomal arms
but lack breakpoint within the affected regions. This
group corresponds to tumors from the clusters b to e
which are characterized by combinations of specific re-
arranged chromosomal arms. The second group corre-
sponds to tumors from the clusters a and f for which it
is not possible to identify a copy number variation
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http://www.biomedcentral.com/1755-8794/5/54affecting an entire chromosome arm, either because of a
flat profile (cluster a) or because of a huge number of
DNA breakpoints (cluster f ). In order to take into ac-
count this distinction, we constructed a genomic index
based on two parameters representing these two kinds
of alterations and showing a continuous distribution of
the tumors with a growing level of alterations (Figure 3).
Adverse outcome was observed for the most highly rear-
ranged genotypes, corresponding mainly to tumors from
clusters e and f.
The transcriptomic intrinsic classification of breast
cancer [10] has led to search for correlations between
the Sorlie classes and specific genomic profiles. It was
effectively possible to correlate the luminal A class with
the simplex profile, the luminal B and the Her2-enriched
classes with the amplifier profile and the basal-like class
with the complex sawtooth profile [1,28,31]. Moreover, a
new classification into six classes taking into account
these correlations was recently proposed [32]. Such a
correlation was also found here between immunohisto-
chemical intrinsic classes and genomic profile. Both the
G2I-1 group and the cluster b (1q gain, 16q loss) are
mainly composed of luminal A tumors (84% and 80%,
respectively). The majority of the tumors belonging to
luminal B and Her2-enriched classes show gene am-
plifications (79% and 90%, respectively). Some results,
conversely, are more surprising. If percentages of lu-
minal A tumors decrease progressively from the G2I-1
to the G2I-2 and G2I-3 groups (respectively, 84%,
62.5% and 43%), the fact that 12 luminal A tumors be-
long to the G2I-3 group was not expected. In the
same way, it is surprising that seven of twelve cluster f
tumors belong to the luminal A class. Seven tumors
belong to the basal-like class. Only one of them ap-
pears in the cluster f and in the G2I-3 group. The six
other basal-like tumors all belong to the G2I-2 group
and to the array CGH cluster a. This cluster, without
any specific chromosomal aneusomy, contains in fact
two subgroups (Figure 1). The first one (right branch)
shows tumors with a flat profile belonging mainly to
the luminal A class. The second one (left branch) in-
cluding the six basal-like tumors shows tumors with-
out chromosomal or chromosomal arm aberrations but
with copy number changes affecting small genomic
regions that are different from one tumor to another.
This profile corresponds to the previously described
subtype of high grade ER-negative tumors with low
genomic instability index [33]. The fact that six out of
seven basal-like tumors did not show metastatic re-
lapse is probably related to a series effect with a small
number of cases. It therefore seems that some breast
carcinomas of luminal A and luminal B phenotypes,
showing important genetic instability with a large num-
ber of DNA breakpoints, frequent TP53 mutations, andfrequent gene amplification are characterized by very
poor outcome.
Prognostic value of genomic alteration in breast cancer
has often been reported. Cytogenetic analysis had previ-
ously shown the correlation between the unbalanced der
(1;16) and good prognosis [34], whereas homogeneously
staining regions or gene amplifications were correlated
with poor outcome [35,36]. These results were con-
firmed by array CGH approaches that show associations
between gene amplification in Her2-enriched and lu-
minal B classes [28,31,37,38], and poor prognosis or be-
tween 16q loss in luminal A tumors and good prognosis
[39]. Subsequently, copy number variation concerning
various genomic regions was shown to be related to out-
come as loss on chromosome arms 19 and 18q [40] or
more complex signatures including several regions, ei-
ther distinct for ER positive and negative tumors [41], or
common for these two kind of tumors [21]. The mea-
surement of genetic instability was not so well documen-
ted. A signature of chromosome instability was inferred
from transcriptomic data as functional aneuploidy re-
lated to a clear deviation in expression of contiguous
genes from the same loci [17]. The application of this
signature to four different published sets of breast can-
cer was highly predictive of outcome [17]. The fraction
of the genome altered (FGA), calculated as the number
of probes affected by gain or loss compared to the total
number of probes represented on the array [42], was
shown to correlate with the classification proposed by
Jonsson et al. in which a higher level of FGA was ob-
served for “basal complex” and “luminal complex” types
of tumors than for the others [32]. The FGA after cor-
rection for tumoral cellularity and named “genome in-
stability index” (GII) fails to find such a correlation but
identified a subtype of basal like tumor with low in-
stability [33]. In association with a three chromosomal
region predictor, the CGH classifier proposed by Gravier
et al. in node negative breast cancer used a measurement
of genomic complexity corresponding after segmentation
to the total number of segmental alterations along the
genome with a threshold of 11. Using this single param-
eter, the prediction of metastatic relapse was highly sig-
nificant (p = 0.00056) [21]. Recently, an array CGH-based
score of genomic complexity called CAAI (Complex arm
aberration index) was shown to have overall independ-
ent prognostic power [43]. All these data indicate that
the type and the level of genetic instability are major
determinants of outcome for breast cancer. These char-
acteristics are probably set up very early during tumor
development, conserved at late stages and common to
any tumoral cell. They can be detected at the level of a
primary tumor, even if only some cell clones will ac-
quire metastatic power. The same explanation could be
offered for the prognostic significance of transcriptomic
Bonnet et al. BMC Medical Genomics 2012, 5:54 Page 16 of 18
http://www.biomedcentral.com/1755-8794/5/54signatures obtained from primary tumors that have been
shown to be mainly related to the proliferative activity of
the tumors [44].
From a clinical point of view, it is interesting to note
that the prognostic value of the G2I is independent of
other major prognostic factors except TP53 mutation
(Table 5). A faint correlation is also found with others
genomic alterations (in particular, the presence of ampli-
cons), with the intrinsic classification and with Mib1 in-
dex but not for classical clinico-pathological parameters
(Table 5). Moreover, the G2I maintains a strong predict-
ive value in subclasses of tumors showing variable out-
comes, such as small tumors, SBR grade 2 and 3 tumors,
hormonal receptors positive tumors and tumors in the
moderate class of the NPI. These data are in favour of
an independent prognostic value for the G2I but evalu-
ation of the benefit in clinical practice will require better
definition of the thresholds used to define the groups
and validation on an unselected population-based set of
tumors. These investigations are currently in progress.
The main result concerns the strong predictive value of the
G2I in tumors without axillary lymph node involvement
since 80% of G2I3 node negative tumors (16 out of 20)
relapsed, whereas only 16% of the G2I-1 and G2I-2 node
negative tumors (9 out of 55) did so (OR: 17.5 [4.6-66.7]
p < 0.001). This information could have major implications
for the indication of adjuvant therapies. The paradox of a
poor outcome for tumors that do not show any evidence
of lymphatic dissemination at the time of local treatment
may suggest that these tumors with high genetic instability
are not lymphophilic, instead showing a hematogenic
mode of diffusion.
Conclusion
Accurate evaluation of genetic instability allows the
identification of a previously unrecognized group of
breast cancers in which a DNA repair defect is probably
involved. From a clinical perspective, the high metastatic
risk observed for this class of tumors indicates that their
treatment should include adjuvant therapies.
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